BNC 105

Known as: BNC-105, BNC105 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2016
012320092016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Microtubule targeting agents, such as vinblastine, are usually thought to arrest cells in mitosis and subsequently induce… (More)
Is this relevant?
2014
2014
BNC105 is a tubulin targeting compound that selectively disrupts vasculature within solid tumors. The severe tumor hypoxia and… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
A structure-activity relationship (SAR) guided design of novel tubulin polymerization inhibitors has resulted in a series of… (More)
Is this relevant?
2011
2011
PURPOSE To determine the recommended phase II dose and evaluate the safety and toxicity profile and pharmacokinetic (PK) and… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2011
2011
Purpose: To determine the recommended phase II dose and evaluate the safety and toxicity profile and pharmacokinetic (PK) and… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2010
2010
Vascular disruption agents (VDA) cause occlusion of tumor vasculature, resulting in hypoxia-driven tumor cell necrosis. Tumor… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2009
2009
e14512 Background: BNC105P is a novel anticancer agent that inhibits tubulin polymerization and acts as a VDA. BNC105P is a… (More)
Is this relevant?